Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ECOG performance status 0-2~* Life expectancy of greater than 12 months~* No prior history of esophageal surgery or endoscopic treatment of dysplasia~* No prior exposure to sorafenib~* Patients may not be receiving any other investigational agents or any concomitant antineoplastic therapy, with the exception of androgen ablating agents (for patients with prior prostate cancer)~* Age 18 years.~* Patients must have adequate organ and marrow function as defined below:~  * hemoglobin: 8.5 g/dL~ * absolute neutrophil count: 1,500/L~ * platelets: 100,000/L (greater than 35,000/L without transfusion for less than 1 X the institutional upper limit of normal)~ * creatinine less than 1.5 X institutional upper limit of normal~* Ability to understand and the willingness to sign a written informed consent.~Exclusion Criteria:~* A patient will be withdrawn from the study if any of the following events occur while on therapy:~  * Interruption of scheduled therapy for greater than 7 days~ * Intolerable adverse effects which are judged by the investigator to be either physically or psychologically detrimental to the patient~ * Patient decision to discontinue treatment~ * Pregnancy~ * Patient non-compliance with therapy administration~ * Grade 3 or 4 NCI-CTC toxicity attributable to sorafenib~ * Treatment with other chemotherapeutic or investigational anti-neoplastic drugs~ * Disease progression~* HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with sorafenib.Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- sorafenib (Type: EXPERIMENTAL): sorafenib 2 tablets by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).